An observational study in Aortic Stenosis, sponsored by World Health Research Inc.. Recruiting at 20 sites in 8 countries. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by World Health Research Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Aortic Valve Stenosis with a site in Canada — 23 open to participants now, 36 under way, 1 of them phase 3. Aortic Valve Stenosis · Canada.
Among the 87 studies in Aortic Valve Stenosis with a site in Canada, this one is the 15th largest by planned enrollment of the 27 observational ones that give a count, is one of 3 that started in 2025, is one of 27 observational ones, reaches primary completion later than 16 of the 35 other live ones, and was the 84th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →23 of the 87 studies in Aortic Valve Stenosis with a site in Canada are open now. Recruiting first, the newest first:
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Sites in Canada
Ages 18+
Kardigan, Inc. · Sites in Canada, United States
Ages 50+
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Sites in Canada
Ages 18–80
Novartis Pharmaceuticals · Sites in Canada, United States, Austria and 12 more countries
Ages 50–80
Edwards Lifesciences · Sites in Canada, United States
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 7 · Phase 4 2
First in 2002; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 290 is above the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 300 across the 60 interventional studies, 320 across the 27 observational. Of the 44 that completed or were terminated, 18 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 87 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with World Health Research Inc. as lead sponsor.
World Health Research Inc. has 1 study filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
8 of the studies in Aortic Valve Stenosis with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06991517World Health Research Inc.A Study of Transcatheter Aortic Valve Replacement Case Selection and Valve Sizing Using the ABC Bicuspid Sizing Algorithm | 2026-12 |
| NCT06816888Ottawa Heart Institute Research CorporationImpact of Automatic Prompts in Echocardiographic Reports on Referral to Cardiology | 2026-12-01 |
| NCT04464655McGill University Health Centre/Research Institute of the McGill University Health CentreA 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease | 2026-12-19 |
| NCT04913870Institut universitaire de cardiologie et de pneumologie de Québec, University LavalAngiotensin Receptor Blockers in Aortic Stenosis | 2027-02 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add all 8 to your calendar (.ics) → With an account.
Among the 87 studies in Aortic Valve Stenosis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to learn what effects the ABC Bicuspid Sizing Algorithm has on the clinical outcomes of patients with bicuspid aortic stenosis after having a transcatheter aortic valve replacement (TAVR) using the Sapien 3 valve. The main questions the study aims to answer are:
Participants already being evaluated for a TAVR as part of their regular medical care for bicuspid aortic stenosis will have their diagnostic images assessed using the ABC Bicuspid Sizing Algorithm to help determine their procedure type and valve size. They will have visits 30 days and annually till 5 years after their procedure.
This is a multi-centre, international, prospective cohort study. Approximately 290 patients who are clinically eligible for transcatheter aortic valve replacement (TAVR) will be enrolled. Using information collected with the ABC Bicuspid Sizing Algorithm, physicians will make a treatment allocation between TAVR and surgical aortic valve replacement (SAVR), and determine valve sizing and deployment for TAVR-treated patients. Included in the algorithm use is the utilization of gated computed tomography evaluation or artificial intelligence-based simulation models in select cases with borderline feasibility. The findings of these additional assessments will be shared with the treating physicians for consideration in the final treatment decision.
Of the 290 patients, an estimated 230 will be recommended to have TAVR. Data will be collected from TAVR-treated patients at baseline, procedure, hospital discharge, and 30 days and annually till 5 years after the procedure. Data will only be collected from SAVR-treated patients at baseline and procedure. Sites in Canada, Latin America, the Middle East, and Asia Pacific will participate.
Patients referred to the TAVR program at select hospitals
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The ABC Bicuspid Sizing Algorithm is a valve sizing algorithm. It guides operators' evaluations of CT scans, helping inform (1) treatment allocation between TAVR and surgical aortic valve replacement, and (2) valve choice for patients undergoing TAVR. In select cases, the algorithm will suggest gated CT evaluation or artificial intelligence-based simulation models be used to further evaluate the risk of the planned valve size and deployment volume. The operators will consider the findings of the ABC Bicuspid Sizing Algorithm as well as other clinical factors when making their final treatment decisions.
Proportion of cases achieving technical success
Freedom from mortality, successful access, delivery of the device, and retrieval of the delivery system, correct positioning of a single prosthetic heart valve into the proper anatomical location, and freedom from surgery or intervention related to the device or cardiac structural complication
Time frame: At exit from procedure room after procedure completion
Proportion of cases achieving device success
Technical success and intended performance of the valve (mean gradient less than 20 mmHg, peak velocity less than 3 m/s, Doppler velocity index greater than 0.35, and less than moderate aortic regurgitation)
Time frame: At 30 days after the procedure
Proportion of cases in which the use of gated computed tomography evaluation or artificial intelligence-based simulation models altered the treatment plan or operator confidence in the treatment plan compared to the ABC Bicuspid Sizing Algorithm alone
Time frame: At baseline
New conduction disturbance and permanent pacemaker implantation
Time frame: At 30 days and 1,3 and 5 years after the procedure
Stroke or transient ischemic attack
Time frame: At 30 days and 1,3 and 5 years after the procedure
Major vascular complication
Time frame: At 30 days after the procedure
Death
Time frame: At 30 days and 1,3 and 5 years after the procedure
Acute valve complication
Time frame: Perioperative/Periprocedural
Need for cardiac surgery
Time frame: At 30 days and 1,3 and 5 years after the procedure
Delayed valve dysfunction
Time frame: At 30 days ,1,3 and 5 years after the procedure
Proportion of cases in which evaluation of anatomy above or below the annulus altered the valve sizing and deployment decision compared to the calculated valve sizing and deployment decision considering the annulus size only
Time frame: At baseline
Hospitalization for acute heart failure
Time frame: 1,3 and 5 years after the procedure
Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.
Of 37 industry-sponsored observational studies under Aortic Valve Stenosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's planned 19 months is below that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.